VCM
PCRX icon

Versant Capital Management’s Pacira BioSciences PCRX Stock Holding History

Versant Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.3K Hold
1,036
– – ﹤0.01% 1787
2026
Q1 		$23.4K Sell
1,036
-76
-7% -$1.69K ﹤0.01% 1724
2025
Q4 		$28.8K Buy
1,112
+42
+4% +$999 ﹤0.01% 1413
2025
Q3 		$27.6K Sell
1,070
-108
-9% -$2.65K ﹤0.01% 1402
2025
Q2 		$28.2K Buy
1,178
+126
+12% +$3.18K ﹤0.01% 1326
2025
Q1 		$26.1K Hold
1,052
– – ﹤0.01% 1192
2024
Q4 		$19.8K Buy
1,052
+206
+24% +$3.62K ﹤0.01% 1037
2024
Q3 		$12.7K Buy
846
+830
+5,188% +$14.2K ﹤0.01% 976
2024
Q2 		$458 Hold
16
– – ﹤0.01% 1805
2024
Q1 		$468 Hold
16
– – ﹤0.01% 1711
2023
Q4 		$540 Sell
16
-12
-43% -$351 ﹤0.01% 1661
2023
Q3 		$859 Sell
28
-18
-39% -$649 ﹤0.01% 1568
2023
Q2 		$1.84K Buy
46
+18
+64% +$744 ﹤0.01% 1403
2023
Q1 		$1.13K Hold
28
– – ﹤0.01% 1413
2022
Q4 		$1.08K Sell
28
-56
-67% -$2.73K ﹤0.01% 1282
2022
Q3 		$4K Buy
84
+78
+1,300% +$4.34K ﹤0.01% 915
2022
Q2 		$0 Sell
6
-35
-85% -$2.29K ﹤0.01% 1591
2022
Q1 		$3K Buy
41
+35
+583% +$2.33K ﹤0.01% 1059
2021
Q4 		$0 Hold
6
– – ﹤0.01% 1553
2021
Q3 		$0 Hold
6
– – ﹤0.01% 1556
2021
Q2 		$0 Sell
6
-113
-95% -$7.15K ﹤0.01% 1560
2021
Q1 		$8K Sell
119
-33
-22% -$2.36K ﹤0.01% 878
2020
Q4 		$9K Hold
152
– – ﹤0.01% 765
2020
Q3 		$9K Hold
152
– – ﹤0.01% 703
2020
Q2 		$7K Buy
152
+84
+124% +$3.51K ﹤0.01% 748
2020
Q1 		$2K Sell
68
-99
-59% -$4.11K ﹤0.01% 1035
2019
Q4 		$7K Buy
+167
New +$7.09K ﹤0.01% 837
2017
Q3 		– Sell
-7
Closed – – 1536
2017
Q2 		$0 Hold
7
– – ﹤0.01% 1514
2017
Q1 		$0 Buy
+7
New +$303 ﹤0.01% 1510

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Versant Capital Management's PCRX Position: Q2 2026 in Review

Versant Capital Management held its Pacira BioSciences (PCRX) position steady in Q2 2026 at 1,036 shares worth $26.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1787.

Versant Capital Management first reported a position in PCRX in Q1 2017 and has held it in 29 quarters since. The position peaked at $28.8K in Q4 2025. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Versant Capital Management held 1,036 shares of Pacira BioSciences worth $26.3K as of Q2 2026.
  • Versant Capital Management left its Pacira BioSciences share count unchanged in Q2 2026.
  • Pacira BioSciences made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #1787 holding.
  • Versant Capital Management first reported a position in Pacira BioSciences in Q1 2017 and has held it in 29 quarters since.
  • Versant Capital Management's Pacira BioSciences position peaked at $28.8K in Q4 2025.
  • 254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.